Adipocyte PHLPP2 inhibition prevents obesity-induced fatty liver

Area of Science:

• Metabolic disease research
• Molecular endocrinology
• Obesity and diabetes mechanisms

Background:

• Increased adiposity is linked to insulin resistance and type 2 diabetes (T2D).
• The precise mechanisms of inter-organ crosstalk in obesity-related metabolic dysfunction are not fully understood.
• PHLPP2 (PH domain and leucine rich repeat protein phosphatase 2), an Akt Ser473 phosphatase, is elevated in adipocytes of obese mice.

Purpose of the Study:

• To investigate the functional role of increased adipocyte PHLPP2 in obesity.
• To determine the impact of adipocyte-specific PHLPP2 deficiency on glucose and lipid homeostasis in diet-induced obesity.

Main Methods:

• Generation of adipocyte-specific PHLPP2 knockout (A-PHLPP2) mice.
• High-fat diet (HFD) feeding to induce obesity and metabolic dysfunction.
• Assessment of adiposity, glucose tolerance, lipolysis, and gene expression (HSL, PPARα, adiponectin).

Main Results:

• A-PHLPP2 mice exhibited reduced adiposity and improved glucose tolerance on HFD compared to controls.
• Loss of adipocyte PHLPP2 increased hormone-sensitive lipase (HSL) phosphorylation and lipolysis.
• This led to enhanced PPARα-dependent adiponectin secretion and increased hepatic fatty acid oxidation, ameliorating fatty liver.

Conclusions:

• Adipocyte PHLPP2 acts as a key regulator of systemic glucose and lipid homeostasis.
• An adipocyte PHLPP2-HSL-PPARα signaling axis influences metabolic health.
• Elevated adipocyte PHLPP2 in obesity contributes to decreased adiponectin and associated metabolic derangements.